Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Bioequivalence Study of Carvedilol Tablets USP 12.5 mg Under Fasting Condition

This study has been completed.
Information provided by (Responsible Party):
IPCA Laboratories Ltd. Identifier:
First received: April 12, 2012
Last updated: July 5, 2012
Last verified: July 2012

This is a randomized, open Label, balanced, two-treatment, two-period, two-sequence, single dose, cross over pivotal study. The purpose of this study is to assess the bioequivalence between Test Product and the corresponding Reference Product under fasting condition in normal, healthy, adult, human subjects.

Condition Intervention Phase
Fasting State
Drug: Carvedilol Tablets USP 12.5 mg
Drug: Carvedilol
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study of Carvedilol Tablets USP 12.5 mg With Coreg® 12.5 mg in Normal, Healthy, Adult, Human Subjects Under Fasting Condition.

Resource links provided by NLM:

Further study details as provided by IPCA Laboratories Ltd.:

Primary Outcome Measures:
  • Bioequivalence is based on Cmax and AUC parameters.Sampling Hours: Pre-dose and at 00.50, 00.75, 01.00, 01.25, 01.50, 01.75, 02.00, 02.50, 03.00, 04.00, 05.00, 06.00, 08.00, 09.00, 10.00, 12.00, 16.00, 20.00, 24.00, 36.00 and 48.00 hours post-dose. [ Time Frame: 5 months ] [ Designated as safety issue: No ]

    Bioequivalence was concluded if:

    The 90% confidence interval of geometric mean ratio of Cmax, AUC0-t and AUC0-inf between test and reference product fall within the range of 80.00 % to 125.00 % for Carvedilol.

Enrollment: 42
Study Start Date: July 2011
Study Completion Date: November 2011
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Carvedilol Tablets USP 12.5 mg
Carvedilol Tablets USP 12.5 mg of M/s Ipca Laboratories Limited, India
Drug: Carvedilol Tablets USP 12.5 mg
12.5mg tablet once a day
Other Name: Test Product
Active Comparator: Coreg®
Coreg® (Carvedilol Tablets) 12.5 mg of M/s GlaxoSmithKline
Drug: Carvedilol
12.5mg tablet once a day
Other Name: Coreg®

Detailed Description:

Objective of this pivotal study was to assess the bioequivalence between Test Product: Carvedilol Tablets USP 12.5 mg of M/s Ipca Laboratories Limited, India and the corresponding Reference Product: Coreg® (Carvedilol Tablets) 12.5 mg Tablets of M/s GlaxoSmithKline, under fasting condition in normal, healthy, adult, human subjects in a randomized crossover study.

The study was conducted with 42 healthy adult subjects. In each study period, a single 12.5 mg dose of either test or reference was administered to the subjects as per the randomization schedule in each study period with about 240 mL of water at ambient temperature in sitting position.

The duration of the clinical phase was approximately 11 days including washout period of at least 7 days between administrations of study drug in each study period.


Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Male and female human subjects, age in the range of 18 - 45 years.
  2. Body weight within ± 15% of ideal weight as related to height and body frame according to Life Insurance Corporation (LIC) Chart.
  3. Subjects with normal findings as determined by baseline history, physical examination and vital signs (blood pressure, pulse rate, respiration rate and oral temperature).
  4. Subjects with clinically acceptable findings as determined by haemogram, biochemistry, serology (HIV, Hepatitis B and Hepatitis C), urinalysis, 12 lead ECG and chest X-ray (chest X-ray if required).
  5. Willingness to follow the protocol requirements as evidenced by written informed consent.
  6. Confirming and agreeing to, not using any prescription and over the counter medications including vitamins and minerals for 14 days prior to study and during the course of the study.
  7. No history of drug abuse in the past one year.
  8. Non-smokers and non-alcoholics.
  9. For female subject is child bearing potential practicing acceptable method of birth control for the duration of the study as judged by Investigator such as Condom, Foams, Jellies,Diaphragm, Intrauterine device and Abstinence.


- is surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy has been performed on the subject).

Exclusion Criteria:

  1. Known history of hypersensitivity to Carvedilol, 4-hydroxyphenyl-carvedilol or related drugs.
  2. Requiring medication for any ailment having enzyme-modifying activity in the previous 28 days, prior to dosing day.
  3. Any medical or surgical conditions, which might significantly interfere with the functioning of gastrointestinal tract, blood-forming organs etc.
  4. History of cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological, metabolic, hematological, gastrointestinal, endocrine, immunological or psychiatric diseases and bleeding tendency.
  5. Participation in a clinical drug study or bioequivalence study within 90 days prior to present study.
  6. History of malignancy or other serious diseases.
  7. Refusal to abstain from food for at least ten (10) hours prior to study drug administration and for at least four (04) hours post-dose, in each study period.
  8. Any contraindication to blood sampling or difficulty in accessibility of veins.
  9. Refusal to abstain from fluid for at least 01.00 hour prior to study drug administration and for at least 01.00 additional hour post-dose, in each study period except about 240 mL of water given during administration of study drug.
  10. Refusal to avoid the use of xanthine-containing food or beverages (chocolates,tea, coffee or cola drinks) or fruit juice/grapefruit juice and any alcoholic products for 48.00 hours prior to dosing until the last blood sample collection of last study period.
  11. Blood donation within 90 days prior to the commencement of the study.
  12. Subjects with positive HIV tests or Hepatitis-B or Hepatitis-C tests.
  13. Found positive in breath alcohol test done before check-in for each study period.
  14. Found positive in urine test for drugs of abuse done before check-in for each study period.
  15. Refusal to abstain from consumption of tobacco products 24 hours prior to dosing until the last blood sample collection of last study period.
  16. History of problem in swallowing Tablets.
  17. Female subject, demonstrating positive urine pregnancy test at the time of screening.
  18. Female subject, demonstrating positive Serum (ß) Beta- hCG (Human Chorionic Gonadotropin) test before check-in for each study period.
  19. Female subject, currently breast feeding or lactating.
  20. Female subjects not willing to use acceptable method of contraception from the date of screening until the completion of the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01577914

Accutest Research Lab (I) Pvt. Ltd.
Ahmedabad, Gujarat, India
Sponsors and Collaborators
IPCA Laboratories Ltd.
Principal Investigator: Dr. Tarang Shah, M.D. Accutest Research Lab (I) Pvt. Ltd.
  More Information

No publications provided

Responsible Party: IPCA Laboratories Ltd. Identifier: NCT01577914     History of Changes
Other Study ID Numbers: Ipca/ARL/203
Study First Received: April 12, 2012
Last Updated: July 5, 2012
Health Authority: India: Ministry of Health
United States: Food and Drug Administration

Additional relevant MeSH terms:
Adrenergic Agents
Adrenergic Antagonists
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists
Adrenergic beta-Antagonists
Antihypertensive Agents
Cardiovascular Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Vasodilator Agents processed this record on February 27, 2015